Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary L Rosner

Showing results (31-40 of 119) with videos related to

Pageof 12
Sort By:
Biostatistics (Oxford, England)|November 29, 2013
Bayesian inference for longitudinal data with non-parametric treatment effectsPeter Müller, Fernando A Quintana, Gary L Rosner, et al.
Journal of the Royal Statistical Society. Series C, Applied Statistics|September 12, 2009
A Semiparametric Bayesian Model for Repeatedly Repeated Binary OutcomesFernando A Quintana, Peter Müller, Gary L Rosner, et al.
Journal of Statistical Theory and Practice|May 21, 2013
Effect on Prediction when Modeling Covariates in Bayesian Nonparametric ModelsAlejandro Cruz-Marcelo, Gary L Rosner, Peter Müller, et al.
Biostatistics (Oxford, England)|July 28, 2018
Individualized treatment effects with censored data via fully nonparametric Bayesian accelerated failure time modelsNicholas C Henderson, Thomas A Louis, Gary L Rosner, et al.
Biometrics|February 13, 2009
Bayesian nonparametric nonproportional hazards survival modelingMaria De Iorio, Wesley O Johnson, Peter Müller, et al.
Biometrics|March 27, 2010
A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studiesVioleta G Hennessey, Gary L Rosner, Robert C Bast, et al.
The American Statistician|September 17, 2013
Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial DesignTheodore G Karrison, Mark J Ratain, Walter M Stadler, et al.
Journal of Statistical Software|July 29, 2011
DPpackage: Bayesian Non- and Semi-parametric Modelling in RAlejandro Jara, Timothy E Hanson, Fernando A Quintana, et al.
Therapeutic Innovation & Regulatory Science|May 8, 2015
Advances in Statistical Approaches Oncology Drug DevelopmentAnastasia Ivanova, Gary L Rosner, Olga Marchenko, et al.
Pharmacogenomics|July 17, 2009
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecanJanelle M Hoskins, Gary L Rosner, Mark J Ratain, et al.
Pageof 12

Showing results (31-40 of 119) with videos related to

Sort By:
Pageof 12
Biostatistics (Oxford, England)|November 29, 2013
Bayesian inference for longitudinal data with non-parametric treatment effectsPeter Müller, Fernando A Quintana, Gary L Rosner, et al.
Journal of the Royal Statistical Society. Series C, Applied Statistics|September 12, 2009
A Semiparametric Bayesian Model for Repeatedly Repeated Binary OutcomesFernando A Quintana, Peter Müller, Gary L Rosner, et al.
Journal of Statistical Theory and Practice|May 21, 2013
Effect on Prediction when Modeling Covariates in Bayesian Nonparametric ModelsAlejandro Cruz-Marcelo, Gary L Rosner, Peter Müller, et al.
Biostatistics (Oxford, England)|July 28, 2018
Individualized treatment effects with censored data via fully nonparametric Bayesian accelerated failure time modelsNicholas C Henderson, Thomas A Louis, Gary L Rosner, et al.
Biometrics|February 13, 2009
Bayesian nonparametric nonproportional hazards survival modelingMaria De Iorio, Wesley O Johnson, Peter Müller, et al.
Biometrics|March 27, 2010
A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studiesVioleta G Hennessey, Gary L Rosner, Robert C Bast, et al.
The American Statistician|September 17, 2013
Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial DesignTheodore G Karrison, Mark J Ratain, Walter M Stadler, et al.
Journal of Statistical Software|July 29, 2011
DPpackage: Bayesian Non- and Semi-parametric Modelling in RAlejandro Jara, Timothy E Hanson, Fernando A Quintana, et al.
Therapeutic Innovation & Regulatory Science|May 8, 2015
Advances in Statistical Approaches Oncology Drug DevelopmentAnastasia Ivanova, Gary L Rosner, Olga Marchenko, et al.
Pharmacogenomics|July 17, 2009
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecanJanelle M Hoskins, Gary L Rosner, Mark J Ratain, et al.
Pageof 12